Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 5, pp. 497-530
Closed Access | Times Cited: 1047

Showing 1-25 of 1047 citing articles:

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott Gettinger, Leora Horn, Leena Gandhi, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 18, pp. 2004-2012
Open Access | Times Cited: 1132
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 6, pp. 491-503
Closed Access | Times Cited: 536
Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies
Tianhong Li, Hsing‐Jien Kung, Philip C. Mack, et al.
Journal of Clinical Oncology (2013) Vol. 31, Iss. 8, pp. 1039-1049
Open Access | Times Cited: 480
Single-cell spatial landscapes of the lung tumour immune microenvironment
Mark Sorin, Morteza Rezanejad, Elham Karimi, et al.
Nature (2023) Vol. 614, Iss. 7948, pp. 548-554
Open Access | Times Cited: 203
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
Antonio Passaro, Jing Wang, Yan Wang, et al.
Annals of Oncology (2023) Vol. 35, Iss. 1, pp. 77-90
Open Access | Times Cited: 166
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
Gilberto de Castro, Iveta Kudaba, Yi‐Long Wu, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 11, pp. 1986-1991
Open Access | Times Cited: 155
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
Shun Lü, Lin Wu, Hong Jian, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 9, pp. 1167-1179
Closed Access | Times Cited: 151
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
Caicun Zhou, Kejing Tang, Byoung Chul Cho, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 22, pp. 2039-2051
Closed Access | Times Cited: 142
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Suzanne L. Topalian, Patrick M. Forde, Leisha A. Emens, et al.
Cancer Cell (2023) Vol. 41, Iss. 9, pp. 1551-1566
Open Access | Times Cited: 123
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC
Caicun Zhou, Benjamin Solomon, Herbert H. Loong, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 20, pp. 1839-1850
Open Access | Times Cited: 109
Emerging Strategies for the Treatment of Small Cell Lung Cancer
W. Jeffrey Petty, Luis Paz‐Ares
JAMA Oncology (2022) Vol. 9, Iss. 3, pp. 419-419
Closed Access | Times Cited: 97
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
Shun Lü, Lin Wu, Hong Jian, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 7, pp. 624-636
Closed Access | Times Cited: 95
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
Byoung Chul Cho, Shun Lu, Enriqueta Felip, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 16, pp. 1486-1498
Closed Access | Times Cited: 83
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
Byoung Chul Cho, Dong‐Wan Kim, Alexander I. Spira, et al.
Nature Medicine (2023) Vol. 29, Iss. 10, pp. 2577-2585
Open Access | Times Cited: 48
From LncRNA to metastasis: The MALAT1-EMT axis in cancer progression
Riya Thapa, Obaid Afzal, Muhammad Afzal, et al.
Pathology - Research and Practice (2023) Vol. 253, pp. 154959-154959
Closed Access | Times Cited: 48
Integration of artificial intelligence in lung cancer: Rise of the machine
Colton Ladbury, Arya Amini, Ameish Govindarajan, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 2, pp. 100933-100933
Open Access | Times Cited: 42
Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET)
Meredith Giuliani, Édith Filion, Sergio Faria, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 120, Iss. 3, pp. 669-677
Open Access | Times Cited: 27
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer
Vincent D. de Jager, Wim Timens, Arnaud Bayle, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100839-100839
Open Access | Times Cited: 24
Radiotherapy and theranostics: a Lancet Oncology Commission
May Abdel‐Wahab, Francesco Giammarile, M. Carrara, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 11, pp. e545-e580
Closed Access | Times Cited: 22
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
Hua Zhong, Shengjie Sun, Jianhua Chen, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 5, pp. 355-365
Closed Access | Times Cited: 16
Evolving Paradigms in Lung Cancer: Latest Trends in Diagnosis, Management, and Radiopharmaceuticals
Busra Cangut, Rahman Akinlusi, Ava Mohseny, et al.
Seminars in Nuclear Medicine (2025)
Closed Access | Times Cited: 1
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System
Chigusa Morizane, Nozomu Machida, Yoshitaka Honma, et al.
JAMA Oncology (2022) Vol. 8, Iss. 10, pp. 1447-1447
Open Access | Times Cited: 60
Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non–Small-Cell Lung Cancer
Dongsheng Yue, Shidong Xu, Qun Wang, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 34, pp. 3912-3917
Closed Access | Times Cited: 43
Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy
Valsamo Anagnostou, Blair V. Landon, Jamie E. Medina, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 670
Open Access | Times Cited: 39
Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
Shenduo Li, Guilherme Sacchi de Camargo Correia, Jing Wang, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2899-2899
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top